Stockbabie NewsFatherMarketNewsMarket Intelligence
MARKETS
Wire · Markets
Markets

Assembly Biosciences To Present New Phase 1a Data From Its ABI-6250 Program At The Liver Meeting 2026

Oct 5, 2026 · 10:01 AM ET· updated 40m ago

Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced that two posters featuring new Phase 1a data from its

Share
Why It Matters

Assembly Biosciences will show early test results for a new medicine at a big conference. When a company shares early data, it signals progress, so watch if doctors and investors react positively.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
ASMB22.57
+0.03 (+0.11%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.